Patents by Inventor Gunther Adolf

Gunther Adolf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TYPE 1 INTERFERON RECEPTOR ANTAGONISTS FOR USE IN METHODS OF TREATING TUBERCULOSIS AND OTHER INFECTIOUS DISEASES
    Publication number: 20200031943
    Abstract: The present invention relates to the use of type 1 interferon receptor antagonists that specifically bind IFNAR1 and/or IFNAR2 and inhibit type 1 IFNs signalling in methods of treating tuberculosis and other infectious diseases, in which type 1 interferon signalling has been found to be deleterious. Infectious diseases that can be treated according to the present invention include tuberculosis and leishmaniasis.
    Type: Application
    Filed: March 21, 2018
    Publication date: January 30, 2020
    Inventors: Matthias WABL, Günther ADOLF
  • Antibodies specific for CD44v6
    Patent number: 7417127
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: August 26, 2008
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Bohringer Ingelheim International GmbH
    Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
  • Antibodies specific for CD44v6
    Patent number: 6972324
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: December 6, 2005
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International, GmbH
    Inventors: Günther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
  • Antibodies specific for CD44v6
    Publication number: 20050214212
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Application
    Filed: May 25, 2005
    Publication date: September 29, 2005
    Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John Miglietta, Augustinus Antonius Van Dongen
  • Antibodies specific for CD44v6
    Publication number: 20030190319
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Application
    Filed: May 20, 2002
    Publication date: October 9, 2003
    Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
  • Vascular anticoagulant proteins DNA which codes them, processer for preparing them and their use
    Patent number: 5837842
    Abstract: This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: November 17, 1998
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rudolf Hauptmann, Ingrid Maurer-Fogy, Gerhard Bodo, Peter Swetly, Christian Stratowa, Edgar Falkner, Gunther Adolf, Christiaan Maria Peter Reutelingsperger
  • Recombinant production of dog and horse type I interferons
    Patent number: 5798228
    Abstract: This invention relates to a process for preparing recombinant horse and dog interferons and the interferons themselves.
    Type: Grant
    Filed: February 24, 1997
    Date of Patent: August 25, 1998
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Adolf Himmler, Rudolf Hauptmann, Norbert Hauel, Gunther Adolf, Peter Swetly
  • Human lysozyme
    Patent number: 5618712
    Abstract: This invention relates to a process for preparing human lysozyme and the human lysozyme protein itself.
    Type: Grant
    Filed: April 4, 1994
    Date of Patent: April 8, 1997
    Assignee: Boehringer Ingelheim Zentrale GmbH
    Inventors: Andrzej Sledziewski, Ewa Chlebowicz-Sledziewska, Peter Swetly, Gunther Adolf, Rudolf Hauptmann, Maria J. Castanon, Walter Spevak
  • Recombinant dog and horse type I interferons
    Patent number: 5605688
    Abstract: This invention relates to a process for preparing recombinant horse and dog interferons and the interferons themselves.
    Type: Grant
    Filed: September 8, 1994
    Date of Patent: February 25, 1997
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Adolf Himmler, Rudolf Hauptmann, Norbert Hauel, Gunther Adolf, Peter Swetly
  • Monoclonal antibodies against IFN-omega, processes for preparing them and their use in the purification and detection of IFN-omega
    Patent number: 5317089
    Abstract: The invention relates to new monoclonal antibodies which react specifically with human interferon of the IFN-omega type but not with other human interferons, and processes for preparing them, and for methods for their use in the purification and detection of IFN-omega.
    Type: Grant
    Filed: September 28, 1987
    Date of Patent: May 31, 1994
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Gunther Adolf
  • Hybrid interferons, their use as pharmaceutical compositions and as intermediate products for the preparation of antibodies and the use thereof and processes for preparing them
    Patent number: 4917887
    Abstract: This invention relates to new hybrid interferons consisting of part of an .alpha.-interferon and part of an omega interferon, the N-terminal Met or N-formyl-Met derivatives thereof and, if the peptide sequence of the hybrid interferon contains a glycosylation site, the N-glycosylated derivatives thereof, their use as pharmaceutical compositions and as intermediate products for immunizing experimental animals and processes for producing them,new monoclonal antibodies and their use in purifying .alpha. and omega-interferons, the hybrid cell lines which secrete them and processes for preparing them,a new process for purifying .alpha. and omega-interferons by means of a new antibody affinity column containing the above-mentioned new monoclonal antibodies, and processes for the preparation thereof,new hybrid plasmids for improving the expression of omega-interferons and new intermediate plasmids for preparing the new plasmids and processes for the preparation thereof.
    Type: Grant
    Filed: March 9, 1987
    Date of Patent: April 17, 1990
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rudolf Hauptmann, Peter Swetly, Peter Meindl, Gunther Adolf, Edgar Falkner, Gerhard Bodo, Ingrid Maurer-Fogy
  • Synergistic mixtures of interferons and tumor necrosis factor
    Patent number: 4791101
    Abstract: Ternary compositions of an interferon of the alpha and/or beta type with an interferon of the gamma type and tumor necrosis factor having a surprising and unexpected synergistic anti-proliferative effect on neoplastic cells when compared to the activity of the individual components of this invention, said compositions being useful in the treatment of neoplasia in animals including humans.
    Type: Grant
    Filed: June 20, 1985
    Date of Patent: December 13, 1988
    Assignee: Boehringer Ingelheim
    Inventor: Gunther Adolf